Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients.

Autor: Barros LL; Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil., Leite G; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Morales W; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Barlow GM; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA., de Azevedo MFC; Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil., de Sousa Carlos A; Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil., Damião AOMC; Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil., Pimentel M; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Farias AQ; Department of Gastroenterology, University of Sao Paulo School of Medicine, Av. Dr. Eneas C Aguiar 255, Sao Paulo-SP, 9117, Brazil. alberto.farias@hc.fm.usp.br.
Jazyk: angličtina
Zdroj: BMC gastroenterology [BMC Gastroenterol] 2024 Dec 03; Vol. 24 (1), pp. 448. Date of Electronic Publication: 2024 Dec 03.
DOI: 10.1186/s12876-024-03509-z
Abstrakt: Background: Despite adequate treatment, a subgroup of patients with inflammatory bowel disease (IBD), including Crohn`s disease and ulcerative colitis, have persistent gastrointestinal symptoms that are not always related to mucosal damage. Recently, two autoantibodies, anti-CdtB and anti-vinculin, were validated as post-infectious IBS (PI-IBS) markers, however there is limited evidence of its diagnostic role in IBD population.
Methods: Patients with more than 3 bowel movements/day and indication of colonoscopy were enrolled. Samples were collected at the time of colonoscopy for assessment of serum levels of anti-CdtB and anti-vinculin antibodies.
Results: A total of 160 subjects were included in 4 groups: active IBD (n = 44); quiescent IBD and chronic diarrhea IBD-IBS (n = 25); predominant-diarrhea IBS (n = 45) and controls (n = 46). The mean value of the optical density for anti-CdtB was 1.2 ± 0.65 in group 1, 1.27 ± 0.64 in group 2, 1.49 ± 0.47 in the group 3 and 1.6 ± 0.68 in group 4, p = 0.012. For anti-vinculin, optical densities were: 1.34 ± 0.78 in group 1, 1.46 ± 0.92 in group 2, 1.31 ± 0.79 in group 3 and 1.41 ± 0.86 for controls (p = 0.875). Using a cut-off of 1.56 for anti-CdtB, the positivity between groups was n = 10 (22.7%) in group 1, n = 9 (34.6%) in group 2, 19 (43.2%) in group 3, 21 (45.7%) in group 4 (p = 0.106). The positivity of anti-vinculin using a cut-off of 1.6 was n = 18 (40.9%) in group 1, n = 11 (42.3%), n = 15 (34.1%), n = 22 (47.8%) (p = 0.622).
Conclusions: Our findings show that anti-CdtB and anti-vinculin could not identify IBD-IBS patients or discriminate IBS-D from healthy controls.
Competing Interests: Declarations. Ethics approval and consent to participate: The study was approved by the Institutional Ethics Review Board of Clinics Hospital, University of São Paulo School of Medicine. Written informed consent was obtained from patients before enrollment. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje